

# GLOBAL VIEW OF CLINICAL TRIAL TRANSPARENCY AND DISCLOSURE EVENTS FOR A SINGLE STUDY AND PRODUCT SUBMISSIONS

Authors: Julie Holtzople, Anne Cutting, Liz Roberts, Steve Kroll, Stephen Bamford, Rene Allard, Chris Pfitzer & Nate Root

## What is the purpose of these pictures?



Global requirements for Clinical Trial Transparency and Disclosure are growing rapidly across the world. This poster is designed to show the numerous Clinical Trial Transparency and Disclosure events over the life of a single study, and over the course of a product submission. We have included the global view for a single study and a full submission. The current scope of this poster is **Phase 1-4 interventional studies** with a single end point and no arms.

The poster demonstrates how the various clinical documents are re-used over time for different publishing and disclosure events over the documents lifecycle. For example, the protocol is used to support registration, will be published with results on the FDA ClinicalTrials.gov site, and is one of the required documents to be publicly shared according to EMA Policy 0070 and potentially additional future global requirements.

\* *One Product Submission normally contains the results of one to many individual studies.*

## STUDY/TRIAL LEVEL CLINICAL TRIAL TRANSPARENCY AND DISCLOSURE EVENTS MET BY INDUSTRY SPONSORS

SCOPE: This picture depicts study specific disclosure requirements for Phase 1-4 interventional studies, driven by Regulations and Legal Policies for current regulations as of Jan 2018. We have also included current requirements, future requirements, Best Practices not mandatory, areas to further explore. (color coded accordingly)



## Definition of Key Terms

- ClinTrials.gov** - ClinicalTrials.gov
- FSI** – First Subject In
- ICF** – Informed Consent Form
- LSLV** – Last Subject Last Visit
- LLS/TRS** – EMA Lay Language Summary aka Trial Results Summary aka Plain Language Summary
- IPLD** – Individual Patient Level Data
- SAP** – Statistical Analysis Plan
- FOIA** – Freedom of Information Act or similar country law for sharing documents
- Publications** – Manuscripts published in journals outside country requirements i.e. ICMJE but are increasingly playing a key role in the way clinical research information is disclosure to the public
- CSR** – Clinical Study Report
- Redacted Package** – This is the term for a package of redacted documents and potentially data delivered to an agency, such as Japan and the EMA. Note, EMA requires Modules 2 and 5, where as Japan requires Modules 1 and 2
- WHO Primary Network Registries** – The World Health Organization has established standards for clinical trial registries. This poster includes those categorized as Primary Registries. These WHO Registry Networks meet specific criteria for content, quality and validity, accessibility, unique identification, technical capacity and administration. Primary Registries also meet the requirements of the ICMJE.

## PRODUCT SUBMISSION CLINICAL TRIAL TRANSPARENCY AND DISCLOSURE EVENTS MET BY INDUSTRY SPONSORS

SCOPE: This picture depicts submission based disclosures driven by global regulators for New Medicines and Line Extensions. We have also included current requirements, future requirements, Best Practices, and areas to further explore. (color coded accordingly)

